Khan Najat

CIK 0002020969

Chief R&D Commercial OfficerDirector

Filings

Latest May 19, 2026

Issuers covered

Showing

11 of 11

Page 1

Track record

3 of 3 open-market trades scored (100% price coverage). Returns are signed: a +10% move on a sale shows as -10% (insider was wrong).

Horizon	Trades	Win rate	Avg	Median	Best	Worst
30 days	3	67%	+4.4%	+3.4%	+14.7%	-4.8%
90 days	2	100%	+26.0%	+26.0%	+26.6%	+25.4%
180 days	1	100%	+37.3%	+37.3%	+37.3%	+37.3%
365 days	-	-	-	-	-	-

Companies where Khan Najat has filed

Ticker	Issuer	Filings	Last filed
RXRX	Recursion Pharmaceuticals, Inc.	11	May 19, 2026

11 Form 4 / 4-A filings, newest first

Filed	Issuer	Top transaction	Shares	Price	Value
May 19, 2026	RXRXRecursion Pharmaceuticals, Inc.	FTax	62,701	$3.04	$190,611
Mar 11, 2026	RXRXRecursion Pharmaceuticals, Inc.	SSale	28,298	$3.3451	$94,660
Feb 19, 2026	RXRXRecursion Pharmaceuticals, Inc.	FTax	14,280	$3.49	$49,837
Feb 10, 2026	RXRXRecursion Pharmaceuticals, Inc.	FTax	10,364	$3.98	$41,249
Dec 29, 2025	RXRXRecursion Pharmaceuticals, Inc.	SSale	124,403	$4.4098	$548,592
Nov 19, 2025	RXRXRecursion Pharmaceuticals, Inc.	FTax	17,584	$4.14	$72,798
Nov 6, 2025	RXRXRecursion Pharmaceuticals, Inc.	AGrant	84,925	$0.00	$0
Aug 19, 2025	RXRXRecursion Pharmaceuticals, Inc.	SSale	36,599	$5.524	$202,173
May 19, 2025	RXRXRecursion Pharmaceuticals, Inc.	FTax	3,796	$4.25	$16,133
Feb 5, 2025	RXRXRecursion Pharmaceuticals, Inc.	FTax	2,753	$7.25	$19,959
Aug 5, 2024	RXRXRecursion Pharmaceuticals, Inc.	AGrant	496,972	$0.00	$0

Showing 1-11 of 11

Page 1 of 1

Real-time Form 4 intelligence. Smarter insider tracking.